Aspen concludes sales agreement for thrombosis business
Pharmaceuticals manufacturer Aspen’s wholly-owned Mauritius-incorporated subsidiary Aspen Global Incorporated (AGI) has concluded an agreement in terms of which Mylan Ireland will acquire the commercialisation rights and related intellectual property of Aspen’s Thrombosis business in Europe for €641.9-million, plus the cost of the related inventory.
In March 2019, Aspen announced that it would undertake a strategic review in respect of its Europe CIS Commercial business. The review has focused on assessing alternative models for the conduct of the business and on determining the range of available options with a view to enhancing the group’s sustainable returns.
In line with the objectives of the strategic review, Aspen is of the view that the disposal of the commercialisation rights to the thrombosis products, while continuing to manufacture and supply the products, is an attractive option.
Mylan is a global pharmaceutical company, with principal offices in Canonsburg, Pennsylvania, in the US. It has a significant presence in Europe, generating sales of more than $4-billion in 2019.
AGI’s thrombosis products are sold under the brand names, and variations of the brand names, including Arixtra, Fraxiparine, Mono-Embolex and Orgaran, in Europe. Mylan has retained AGI as its distributor of the thrombosis products in France.
The transaction will be conditional upon the fulfilment of customary conditions precedent applicable to transactions of this nature, and the transaction is expected to be concluded before December 31.
In terms of the transaction, the disposal of the assets comprises those relating exclusively to the thrombosis products in Europe, including intellectual property required for their commercialisation, and any related goodwill owned by AGI and its subsidiaries, product registrations and marketing authorisations, and the related inventory.
The proceeds from the transaction will be used to reduce Aspen’s debt.
Further, the transfer to Mylan of employees engaged in the thrombosis business will take place in accordance with European labour law regulations.
Contemporaneously with the transaction, Aspen and Mylan will enter into a manufacturing and supply agreement in terms of which Aspen will supply thrombosis products to Mylan for the territory.
Comments
Press Office
Announcements
What's On
Subscribe to improve your user experience...
Option 1 (equivalent of R125 a month):
Receive a weekly copy of Creamer Media's Engineering News & Mining Weekly magazine
(print copy for those in South Africa and e-magazine for those outside of South Africa)
Receive daily email newsletters
Access to full search results
Access archive of magazine back copies
Access to Projects in Progress
Access to ONE Research Report of your choice in PDF format
Option 2 (equivalent of R375 a month):
All benefits from Option 1
PLUS
Access to Creamer Media's Research Channel Africa for ALL Research Reports, in PDF format, on various industrial and mining sectors
including Electricity; Water; Energy Transition; Hydrogen; Roads, Rail and Ports; Coal; Gold; Platinum; Battery Metals; etc.
Already a subscriber?
Forgotten your password?
Receive weekly copy of Creamer Media's Engineering News & Mining Weekly magazine (print copy for those in South Africa and e-magazine for those outside of South Africa)
➕
Recieve daily email newsletters
➕
Access to full search results
➕
Access archive of magazine back copies
➕
Access to Projects in Progress
➕
Access to ONE Research Report of your choice in PDF format
RESEARCH CHANNEL AFRICA
R4500 (equivalent of R375 a month)
SUBSCRIBEAll benefits from Option 1
➕
Access to Creamer Media's Research Channel Africa for ALL Research Reports on various industrial and mining sectors, in PDF format, including on:
Electricity
➕
Water
➕
Energy Transition
➕
Hydrogen
➕
Roads, Rail and Ports
➕
Coal
➕
Gold
➕
Platinum
➕
Battery Metals
➕
etc.
Receive all benefits from Option 1 or Option 2 delivered to numerous people at your company
➕
Multiple User names and Passwords for simultaneous log-ins
➕
Intranet integration access to all in your organisation